Results 1 to 10 of about 2,397,304 (343)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy

Frontiers in Endocrinology, 2021
Pancreatic neuroendocrine tumors (pNETs) are rare and part of the diverse family of neuroendocrine neoplasms (NENs). Somatostatin receptors (SSTRs), which are widely expressed in NENs, are G-protein coupled receptors that can be activated by ...
Yuheng Hu, Zeng Ye, Fei Wang, Yi Qin, Xiaowu Xu, Xianjun Yu, S. Ji   +6 more
semanticscholar   +3 more sources

Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease [PDF]

Acta Neuropathologica, 2015
Alzheimer's disease and other age-related neurodegenerative disorders are associated with deterioration of the noradrenergic locus coeruleus (LC), a probable trigger for mood and memory dysfunction.
Adori, C., Barde, S., Bölcskei, Kata, Gluck, L., Kovacs, G. G., Maglóczky, Zsófia, Palkovits, Miklós, Szolcsányi, János, Yoshitake, T.   +8 more
core   +2 more sources

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

European Journal of Nuclear Medicine and Molecular Imaging, 2022
The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications,
K. Sjögreen Gleisner, N. Chouin, P. M. Gabiña, F. Cicone, S. Gnesin, C. Stokke, M. Konijnenberg, Marta Cremonesi, F. Verburg, P. Bernhardt, U. Eberlein, J. Gear   +11 more
semanticscholar   +1 more source

Pasireotide—a novel somatostatin receptor ligand after 20 years of use

Reviews in Endocrine & Metabolic Disorders, 2022
Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs.
M. Bolanowski, M. Kałużny, P. Witek, A. Jawiarczyk-Przybyłowska   +3 more
semanticscholar   +1 more source

The Future of Somatostatin Receptor Ligands in Acromegaly

Journal of Clinical Endocrinology and Metabolism, 2021
Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of ...
M. Gadelha, L. E. Wildemberg, L. Kasuki
semanticscholar   +1 more source

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

Frontiers in Oncology, 2020
Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs.
Wei Wu, Yunxiang Zhou, Yali Wang, Lihong Liu, Jianyao Lou, Yongchuan Deng, P. Zhao, Anwen Shao   +7 more
semanticscholar   +1 more source

High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma *

British Journal of Dermatology, 2020
Merkel cell carcinoma (MCC) is an aggressive, high‐grade, cutaneous neuroendocrine tumour (NET). Agents blocking programmed death 1/programmed death ligand 1 have efficacy in metastatic MCC (mMCC), but half of patients do not derive durable benefit ...
T. Akaike, J. Qazi, A. Anderson, F. Behnia, M. Shinohara, G. Akaike, D. Hippe, H. Thomas, S. Takagishi, K. Lachance, S. Y. Park, E. Tarabadkar, J. Iyer, A. Blom, U. Parvathaneni, H. Vesselle, P. Nghiem, S. Bhatia   +17 more
semanticscholar   +1 more source

Somatostatin Receptor

Definitions, 2020
Somatostatin receptor is a family of G protein-coupled seven transmembrane receptors. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins.
SSTRs Sstr
semanticscholar   +1 more source

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source

The pathophysiological consequences of somatostatin receptor internalization and resistance [PDF]

, 2003
Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors.
Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven)   +1 more
core   +3 more sources